Monitoring Thyroid Function in Patients on Levothyroxine. Assessment of Conformity to National Guidance and Variability in Practice

Abstract

Introduction

With demand for endocrine tests steadily increasing year-on-year, we examined thyroid function test (TFT) frequencies in patients on levothyroxine replacement therapy to assess the effect of initial TFT results and request source on TFT re-testing interval.

Methods

All TFTs performed by the Clinical Biochemistry Departments at the Salford Royal Hospital (2009–2012; 288 263 requests from 139 793 patients) and University Hospital of North Midlands (2011–2014; 579 156 requests from 193 035 patients) were extracted from the laboratory computer systems. Of these, 54 894 tests were on 13 297 patients confirmed to be on levothyroxine therapy in the test cohort (Salford) and 67 298 requests on 11 971 patients in the confirmatory cohort (North Midlands).

Results

In the test cohort, median TFT re-testing interval in the total group was 19.1 weeks (IQR 9.1–37.7 weeks), with clearly defined peaks in TFT re-testing evident at 6 and 12 months and a prominent broad peak at 1–3 months. Median re-test interval was much lower than recommended (52 weeks) for those with normal TFTs at 31.3 weeks (30.6 weeks for the confirmatory cohort). Where thyroid-stimulating hormone (TSH) was elevated and free thyroxine (fT4) was below the reference range, re-test interval was much longer than is recommended (8 weeks) at 13.4–17.6 weeks (7.1–23.4 weeks in the confirmatory cohort), as was the interval when TSH was below and fT4 was above the normal range, at 16.7–25.6 weeks (27.5–31.9 weeks in the confirmatory cohort).

Conclusion

Our findings show that the majority of TFT requests are requested outside recommended intervals and within-practice variability is high. A new approach to ensuring optimum monitoring frequency is required. Direct requesting from the clinical laboratory may provide one such solution.

Key words

Monitoring - thyroid function - frequency - guidance

• References

• 1 Lord Carter of Coles. Report of the Second Phase of the Review of NHS Pathology Services in England (December 2008). An independent review for the Department of Health, UK http://webarchive.nationalarchives.gov.uk/20130107105354/http:/www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_091984.pdf (Last accessed: 06/07/2015)
• 2 Fryer AA, Hanna FW. Managing demand for pathology tests: financial imperative of duty of care?. Ann Clin Biochem 2009; 46: 435-437
• 3 Janssens PMW. Managing the demand for laboratory testing: Options and opportunities. Clin Chim Acta 2010; 411: 1596-1602
• 4 Smellie WSA. Demand management and test request rationalization. Ann Clin Biochem 2012; 49: 323-336
• 5 Jackson BR. Managing laboratory test use: principles and tools. Clin Lab Med 2007; 27: 733-748
• 6 Rao GG, Crook M, Tillyer ML. Pathology tests: is the time for demand management ripe at last?. J Clin Pathol 2003; 56: 243-248
• 7 Fryer AA, Smellie WSA. Managing demand for laboratory tests: a laboratory toolkit. J Clin Pathol 2013; 66: 62-72
• 8 Vanderpump MP, Tunbridge WM, French JM. et al. The incidence of thyroid disorders in the community; a twenty-year follow up of the Whickham survey. Clin Endocrinol 1995; 43: 55-69
• 9 Beckett GJ, Toft AD. First-line thyroid function tests – TSH alone is not enough. Clin Endocrinol 2003; 58: 20-21
• 10 Keele University Benchmarking Service. www.keele.ac.uk/benchmarking (Last accessed: 06/07/2015)
• 11 Association of Clinical Biochemistry/British Thyroid Association. UK Guidelines for the Use of Thyroid Function tests (July 2006) http://www.british-thyroid-association.org/info-for-patients/Docs/TFT_guideline_final_version_July_2006.pdf (Last accessed: 06/07/2015)
• 12 The Association of Clinical Biochemistry and Laboratory Medicine/The Royal College of Pathologists. National Minimum Re-testing Interval Project: A final report detailing consensus recommendations for minimum re-testing intervals for use in Clinical Biochemistry (2013). http://www.acb.org.uk/docs/default-source/committees/scientific/guidelines/acb/acb-mri-recommendations-a4-computer.pdf?sfvrsn = 2 (Last accessed: 06/07/2015)
• 13 American Thyroid Association http://www.thyroid.org/thyroid-guidelines/ (Last updated: 06/07/2015)
• 14 Driskell OJ, Holland D, Hanna FW. et al. Inappropriate requesting of HbA1c is widespread: Assessment of prevalence, impact of national guidance and practice-to-practice variability. Clin Chem 2012; 58: 906-915
• 15 Driskell OJ, Holland D, Waldron JL. et al. Reduced testing frequency for glycated haemoglobin, HbA1c, is associated with deteriorating diabetic control. Diabetes Care 2014; 37: 2731-2737
• 16 Zhi M, Ding EL, Theisen-Toupal J. et al. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. PLoS One 2013; 8: e78962
• 17 Werhun A, Hamilton W. Thyroid function testing in primary care: overused and under-evidenced? A study examining which clinical features correspond to an abnormal thyroid function result. Fam Pract 2015; 32: 187-191
• 18 Livingston M, Twomey PJ, Basu A. et al. Should Free Thyroxine Go Back into the Routine Thyroid Profile?. Exp Clin Endocrinol Diabetes 2015; 123: 594-597
• 19 Razvi S, Ingoe L, Keeka G. et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 1715-1723